Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Volunteer Compensation and Reimbursement – V 2.0

Posted on By

BA-BE Studies: SOP for Volunteer Compensation and Reimbursement – V 2.0

Standard Operating Procedure for Volunteer Compensation and Reimbursement in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/085/2025
Supersedes SOP/BA-BE/085/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a standardized procedure for providing compensation and reimbursement to volunteers who participate in Bioavailability/Bioequivalence (BA/BE) studies in compliance with ethical standards and applicable regulatory requirements.

2. Scope

This SOP applies to the finance, clinical, and administrative staff involved in the calculation, approval, documentation, and disbursement of compensation to study volunteers across all BA/BE studies conducted at the clinical site.

3. Responsibilities

  • Finance Department: Calculates and processes payment according to approved budget and study plan.
  • CRC: Maintains subject participation records and verifies completion status for eligibility.
  • Investigator: Approves compensation disbursement and verifies absence of protocol violations.
See also  BA-BE Studies: SOP for Reference Product Selection and Procurement - V 2.0

4. Accountability

The Study Director is accountable for ensuring volunteers receive compensation as approved by the Ethics Committee, in a timely and transparent manner.

5. Procedure

5.1 Determination of Compensation

  1. Compensation is based on:
    • Ethics Committee approved amount
    • Duration of stay and study participation
    • Study-related inconvenience or risk
  2. Reimbursement includes:
    • Travel expenses
    • Meal coupons or actual meal costs

5.2 Eligibility Criteria

  1. Volunteers who complete the study period without major protocol violations are eligible.
  2. Partial compensation may be given in case of withdrawal due to medical reasons or investigator discretion.

5.3 Approval Process

  1. CRC verifies subject ID and completion of all protocol activities.
  2. Prepare Annexure-1: Compensation Approval Sheet and get PI sign-off.
  3. Finance department reviews and disburses payments accordingly.
See also  BA-BE Studies: SOP for Trial Registration with EudraCT - V 2.0

5.4 Disbursement

  1. Payments shall be made:
    • By cheque, direct bank transfer, or UPI
    • In the presence of a witness (when in cash)
  2. Documented in Annexure-2: Volunteer Payment Register signed by recipient.

5.5 Handling Discrepancies

  1. Any payment discrepancy or dispute must be recorded in Annexure-3: Compensation Discrepancy Log and resolved within 5 working days.

5.6 Confidentiality and Recordkeeping

  1. Volunteer financial information shall be maintained confidentially in secure files.
  2. Retention period for records shall be at least 5 years or as per sponsor/regulatory requirements.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CRC: Clinical Research Coordinator
  • EC: Ethics Committee
  • PI: Principal Investigator

7. Documents

  1. Compensation Approval Sheet – Annexure-1
  2. Volunteer Payment Register – Annexure-2
  3. Compensation Discrepancy Log – Annexure-3

8. References

  • Indian GCP Guidelines
  • ICH E6(R2) Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules, India
See also  BA-BE Studies: SOP for Developing Study Synopsis for Ethics Submission - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Compensation Approval Sheet

Subject ID Study Code Amount Approved (₹) Approved By (PI) Date
VOL-085 BE/2025/003 7,500 Dr. Arvind Shah 17/04/2025

Annexure-2: Volunteer Payment Register

Subject ID Payment Mode Amount Paid Paid By Signature
VOL-085 UPI ₹7,500 Sunita Reddy Rajesh Kumar

Annexure-3: Compensation Discrepancy Log

Date Subject ID Issue Resolution Handled By
17/04/2025 VOL-085 Bank details mismatch Paid in cash with witness CRC

Revision History:

Revision Date Revision No. Details Reason Approved By
12/01/2022 1.0 Initial SOP Release EC Approved Process QA Head
17/04/2025 2.0 Included Annexures for Transparency and UPI mode Operational Update QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Biosimilars: SOP for Cryopreservation of Cell Banks – V 2.0
Next Post: API Manufacturing: SOP for Seeding Techniques in Crystallization – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version